FindDrugs.org

Embody Weight Loss / GLP-1 Review

Weight Loss / GLP-1 · Reviewed Sep 20, 2026

5.90/10
Embody operator trust5.62/10See the full Embody brand review
Cash-pay

Our verdict

Embody is a cash-pay compounded GLP-1 service operated by Modern Metabolic Medicine, Inc. It publishes its full price ladder before signup, charges no membership fee, and names the four pharmacies that dispense its medication — all three unusual in this category. It also takes payment before a clinician confirms eligibility, refunds nothing once paid unless the provider disqualifies the patient, and does not publish the states it serves or the doses it prescribes.

Price

from $79/mo · 2 plans

Visit Embody

We may earn a commission if you sign up through this link. It never affects rankings or scores. Not medical advice.

Key takeaways

  • Compounded semaglutide from $79 for one month or $828 for twelve; tirzepatide from $129 or $1,428 for twelve
  • Prices are public product pages — no quiz needed to see the cost, and no membership fee
  • The clinician consultation deciding eligibility happens after checkout
  • No refund once payment is submitted, except on provider-initiated medical disqualification
  • Four dispensing pharmacies named with addresses; no pharmacy-classification detail published
  • States served are not published

What is Embody Weight Loss / GLP-1?

Embody sells compounded semaglutide and compounded tirzepatide by term: one, three, six or twelve months. A patient picks a term, pays, completes an intake, and is then evaluated by a clinician from OpenLoop Health, a third-party network of US-licensed doctors that Embody names on its contact page. Medication is dispensed by one of four named partner pharmacies and shipped. Clinical questions go through a patient portal and are answered by a licensed clinician.

Treatment options

Prices as of Sep 20, 2026 — verify current on the brand's site.

Getting started with Embody

  1. Choose a medication and a term length on the site — the price is shown before any questionnaire
  2. Pay for the term
  3. Complete the medical intake
  4. An OpenLoop Health clinician reviews the intake and meets the patient to decide whether to prescribe
  5. If prescribed, one of the four named partner pharmacies dispenses and ships the medication

Methodology scorecard

Scored on Sep 20, 2026 under methodology v6

5.90/10
  • Legitimacy & Accreditation
    Critical

    Evidence (as scored Sep 20, 2026): Transparent corporate identity — Modern Metabolic Medicine, Inc. is named as the legal entity operating Embody, with a US phone number and support address. No third-party accreditation is claimed anywhere on the site, and none was verified. Nothing on the FDA's enforcement register or the federal court docket. — joinem.co, Sep 19, 2026

  • Clinical Oversight & Safety
    Critical

    Evidence (as scored Sep 20, 2026): Care is delivered through OpenLoop Health, a named third-party US-licensed clinician network, with a stated exclusionary-criteria screen. No individual clinician is named anywhere on the site. The qualifying consultation happens AFTER checkout. — joinem.co, Sep 19, 2026

  • Sourcing Transparency & Legal Context
    High

    Evidence (as scored Sep 20, 2026): Partner pharmacies include: Red Rock Compounding Pharmacy — https://www.redrockhomepharmacy.com — 240 East 100 South, Suite 220 St. George, UT 84790 435-703-2900 Health Warehouse — https://www.healthwarehouse.com — 7107 Industrial Rd. Florence, KY 41042 800-748-7001 Precision Medicine — https://prec — joinem.co, Sep 19, 2026

  • Data Privacy & Security
    Medium

    Evidence (as scored Sep 20, 2026): Publishes a privacy policy, a separate notice of privacy practices, a California-residents notice, a data-sharing opt-out page and a TCPA policy. No public breach record was found. Depth of security posture is not independently auditable. — joinem.co, Sep 19, 2026

  • Pricing Transparency & Value
    Critical

    Evidence (as scored Sep 20, 2026): Compounded Semaglutide (GLP-1) — $79.00, compare-at $299.00 (product JSON, retrieved 2026-09-19). — joinem.co, Sep 19, 2026

  • Policy Clarity & Fairness
    High

    Evidence (as scored Sep 20, 2026): The policy is clearly written and highly unfavourable. No refunds of any kind once payment is submitted, with a single exception for provider-initiated medical disqualification; no proration; no credit for undelivered or unshipped medication; subscriptions auto-renew. Cancellation is available at any time but refunds nothing already paid. — joinem.co, Sep 19, 2026

  • Popularity & Momentum
    Medium

    Evidence (as scored Sep 20, 2026): Substantial and currently active paid-search demand: $44,730 of measured spend in a single month across 4,986 clicks and 435 conversions, plus 13 affiliate placements on one network. An active CRM advertiser since March 2026.

  • Access & Speed
    Medium

    Evidence (as scored Sep 20, 2026): Mail-order fulfilment through four named pharmacies. The states served are not published and must be requested from support, so a prospective patient cannot determine availability before starting. No turnaround-time commitment is published. — joinem.co, Sep 19, 2026

  • Transparency & Disclosure
    Critical

    Evidence (as scored Sep 20, 2026): Strong on medication risk and pharmacy identity: a black-box thyroid C-cell warning, an explicit statement that compounded drugs are not FDA-approved, and four named partner pharmacies with street addresses and phone numbers. Weak on operations: the states served are not published, and eligibility criteria are not visible before checkout. — dailymed.nlm.nih.gov, Aug 11, 2026

  • Support & Care Model
    Supporting

    Evidence (as scored Sep 20, 2026): A patient portal routes clinical questions to a licensed clinician, with published email and a US phone number for non-clinical support. No coaching programme, and no published support hours or response-time commitment. — joinem.co, Sep 19, 2026

  • Titration Autonomy
    High

    Evidence (as scored Sep 20, 2026): *Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity. — dailymed.nlm.nih.gov, Aug 11, 2026

  • Weight-Management Care Model
    Medium

    Evidence (as scored Sep 20, 2026): What Your First 6 Months on Embody Really Look Like Month 0–1: Getting Started & Adjusting ... Month 4–6: Sustainable, Ongoing Results — joinem.co, Sep 19, 2026

  • Eligibility Screening
    High

    Evidence (as scored Sep 20, 2026): Do not take them if you have ever had thyroid cancer. ... Do not take this medication if pregnant, trying to get pregnant or breastfeeding. — dailymed.nlm.nih.gov, Aug 11, 2026

Pricing & cancellation

Visit Embody

All-in price

from $79/mo · 2 options

Cost structure
Programmes auto-renew; consent to automatic charging is embedded in the medical consent form.
Insurance vs. cash
Cash-pay
Deal structure
Cancellation
Cancel any time by email, phone or patient portal; cancellation refunds nothing already paid.
Forced subscription
Required

Pros & cons

Pros

  • Publishes the full price ladder pre-signup as public product pages, with no separate membership or consultation fee
  • Names four dispensing pharmacies with street addresses, phone numbers and websites — most of this category names none
  • Names its operating legal entity, Modern Metabolic Medicine, Inc., and its clinician network, OpenLoop Health
  • Publishes a dedicated GLP-1 safety page carrying the black-box thyroid C-cell warning and an explicit statement that compounded drugs are not FDA-approved
  • The FDA's enforcement register and the federal court docket both return nothing, verified against both primary sources

Cons

  • No refunds once payment is submitted, except on provider-initiated medical disqualification — no proration, and no credit for medication never shipped
  • The qualifying clinician consultation happens after checkout, so a patient pays before learning whether they are eligible
  • The list of states served is not published and must be requested from customer support
  • No dose, strength or titration detail is published for either medication
  • No LegitScript, NABP or URAC accreditation is claimed or verifiable
  • Struck-through comparison prices of $299 and $349 are not substantiated anywhere on the site

Safety

Talk to a licensed clinician

Embody publishes a dedicated GLP-1 safety page. It carries the boxed warning for thyroid C-cell tumours that the approved labels for these molecules also carry, and states that compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness or manufacturing quality. The commonly reported side effects of this drug class are gastrointestinal — nausea, vomiting, diarrhoea and constipation. The safety page also lists the warning signs it associates with pancreatitis, gallbladder problems, kidney injury from dehydration, and thyroid C-cell tumours, and directs patients to report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch. FindDrugs cites the DailyMed prescribing information and the Drugs@FDA approval record for the clinical facts themselves; Embody's own page is cited for what Embody discloses.

Common side effects

  • Nausea, vomiting, diarrhoea and constipation are the commonly reported GLP-1 side effects
  • Pancreatitis — Embody's safety page lists severe abdominal or back pain that will not go away as a warning sign
  • Thyroid C-cell tumour risk carries a black-box warning; Embody lists trouble swallowing, hoarseness, a neck lump or swelling, or shortness of breath
  • Gallbladder problems and kidney injury from dehydration are listed on the safety page
  • Embody directs patients to report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch

Who should not take it

  • Personal or family history of medullary thyroid carcinoma or MEN2 — Embody's safety page says not to take these medications if you have ever had thyroid cancer
  • Pregnancy, trying to become pregnant, or breastfeeding — the safety page says to stop at least two months before trying to conceive
  • History of pancreatitis
  • Patients on thyroid hormone medication are told to review timing with their prescribing doctor

The bottom line

Embody suits someone who has already decided on compounded GLP-1 treatment, wants to know the total cost before starting, and is willing to pay up front and non-refundably for it. Anyone who wants to confirm eligibility before paying, know which state coverage applies, or see the dose they will be prescribed should look elsewhere or ask those questions of support before checkout.

Visit Embody

We may earn a commission if you sign up through this link. It never affects rankings or scores. Not medical advice.

See how Embody ranks among GLP-1 providers

Work at Embody?

If something here is wrong or out of date, send us a correction request. We read every one and decide what changes — it does not edit the review or move a score.

Sources & how we researched this

Scored on 13 of 14 factors · 16 sources cited

Regulatory

Other

  • joinem.co · joinem.co · Retrieved Sep 19, 2026
  • joinem.co · joinem.co · Retrieved Sep 19, 2026
  • joinem.co · joinem.co · Retrieved Sep 19, 2026
  • joinem.co · joinem.co · Retrieved Sep 19, 2026
  • joinem.co · joinem.co · Retrieved Sep 19, 2026
  • joinem.co · joinem.co · Retrieved Sep 19, 2026
  • joinem.co · joinem.co · Retrieved Sep 19, 2026
  • joinem.co · joinem.co · Retrieved Sep 19, 2026
  • joinem.co · joinem.co · Retrieved Sep 19, 2026
  • joinem.co · joinem.co · Retrieved Sep 19, 2026
  • joinem.co · joinem.co · Retrieved Sep 19, 2026
  • joinem.co · joinem.co · Retrieved Sep 19, 2026
  • joinem.co · joinem.co · Retrieved Sep 19, 2026

What we couldn't verify

  • No BMI threshold or minimum age is published. The intake page returns 101 characters to a raw fetch, and the eligibility questionnaire is not in the served HTML. The skill's intake-flow walkthrough would reach it, but that requires a rendered fetch, and joinem.co is recorded stance 'refused' — the sanctioned exception covers raw retrieval only.
  • No dose, strength, vial size or titration schedule is published for either medication.
  • The list of states served is not published; Embody directs prospective patients to email support.
  • No pharmacy-classification detail is published for any of the four named dispensing pharmacies.
  • No consumer-sentiment data. Trustpilot is recorded stance 'refused' with robots.txt 'Disallow: /' and terms banning automated access; no rating or count was retrieved and none is published. This is our constraint, not brand opacity — the factor is excluded, not scored low.
  • Third-party accreditation status was not checked against the registries this run. No accreditation is claimed on the site, so nothing is being repeated unverified, but the directories were not queried.
  • The struck-through comparison prices of $299 and $349 on the one-month product pages are not substantiated anywhere on the site.
  • NAD+, sermorelin, glutathione and MIC/B12 intake pages exist but carry no product, price or clinical detail. They are recorded as discovered offerings and are NOT scored or reviewed this run — the research to score them was not done, and a thin score is worse than none.
  • The CRM record lists ED as a sub-vertical for this advertiser. No ED product, intake page or mention appears anywhere in the site's own sitemap or on any retrieved page. Recorded as a CRM/site discrepancy, not as a vertical.
  • The absence of any entry on the FDA's enforcement register and of federal litigation is recorded as METHOD in the relevant observations' notes, not as a citation. A search URL is a query, not a record — `classifyFdaCitation` refuses to classify one, and it is right to: citing a search result as a primary source would let "I looked and found nothing" render as a cited fact. The federal-docket check ran on 2026-09-21 against the CourtListener REST API v4 (the only sanctioned route — courtlistener.com is refused on terms), with the positive control "Mochi Health" returning 15 records, so a zero result from this run is a measurement and not a failed search. The legal entity "Modern Metabolic Medicine, Inc" returns 0 records — a measured absence. The brand-name query "Embody" returns 24,378 records, but no case caption contains the string: "embody" is an ordinary English word matching case body text, so that query supports no claim in either direction and the absence rests on the legal-entity query alone. This check did NOT run before this review was first published; it was added afterwards.
  • The drug-label and regulatory records attached to the safety, dosing and approval claims (DailyMed WEGOVY, Drugs@FDA NDA 217806, the FDA compounded-GLP-1 action) are REUSED from records the corpus already holds for the same drugs — they carry no quote, because their text was not retrieved in this run. The citation is to the record; the wording of the record is not restated.
  • The paid-search and affiliate-placement figures come from internal commercial records (the WebMD term analysis and the RX position log), which are not public sources and belong to no citation tier. They are recorded as METHOD in the observations' notes, not as citations — a file path on disk is provenance for a figure, not a source a reader can check, and rendering it as one would put an uncheckable citation on a published page.
Last reviewed Sep 20, 2026 · methodology v6View the ledger

Top pick

Embody 5.90/10